Table III AMD risk for all AMD based on genotype and CEP markers

Odds ratios were determined for all AMD risk based on genotype alone or based on the joint effect of genotype plus elevated levels of both CEP markers relative to median control levels (≥19 pmol/ml CEP adducts and ≥1.3 CEP autoantibody titer). Odds ratios and 95% CI involving CEP markers are based on log-transformed concentrations.

AMD risk genotypeGenotype frequency (%)Odds ratio (95% CI)
ControlAMDGenotype onlyJoint effect CEP adducts and autoantibodies
Not both elevatedBoth elevated
ARMS2n = 404n = 708
    GG246 (60.9%)278 (39.3%)1.00 (reference)1.00 (reference)2.75 (1.92, 3.95)
    GT143 (35.4%)306 (43.2%)1.89 (1.46, 2.46)1.87 (1.32, 2.65)4.82 (3.26, 7.14)
    TT15 (3.7%)124 (17.5%)7.32 (4.17, 12.84)6.16 (3.00, 12.66)20.88 (8.22, 53.04)
HTRA1n = 229n = 747
    GG134 (58.5%)294 (39.4%)1.00 (reference)1.00 (reference)2.90 (1.84, 4.57)
    GA78 (34.1%)279 (37.3%)1.63 (1.18, 2.25)1.90 (1.26, 2.86)3.23 (2.01, 5.18)
    AA17 (7.4%)174 (23.3%)4.66 (2.72, 7.99)4.21 (2.06, 8.60)10.61 (4.74, 23.71)
CFHn = 381n = 788
    TT161 (42.3%)160 (20.3%)1.00 (reference)1.00 (reference)2.55 (1.62, 4.02)
    TC172 (45.1%)384 (48.7%)2.25 (1.69, 2.98)2.19 (1.50, 3.20)6.17 (4.03, 9.45)
    CC48 (12.6%)244 (31.0%)5.12 (3.50, 7.47)6.13 (3.74, 10.06)10.65 (5.90, 19.20)
C3n = 343n = 769
    CC198 (57.7%)317 (41.2%)1.00 (reference)1.00 (reference)2.84 (1.96, 4.13)
    CG114 (33.2%)270 (35.1%)1.48 (1.12, 1.96)1.62 (1.11, 2.34)3.71 (2.43, 5.68)
    GG31 (9.1%)182 (23.7%)3.67 (2.41, 5.58)4.52 (2.69, 7.60)8.87 (4.28, 18.37)